HK1014669A1 - Use of tetrahydrocarbazole derivatives as 5ht1-receptor agonists - Google Patents

Use of tetrahydrocarbazole derivatives as 5ht1-receptor agonists

Info

Publication number
HK1014669A1
HK1014669A1 HK98116054A HK98116054A HK1014669A1 HK 1014669 A1 HK1014669 A1 HK 1014669A1 HK 98116054 A HK98116054 A HK 98116054A HK 98116054 A HK98116054 A HK 98116054A HK 1014669 A1 HK1014669 A1 HK 1014669A1
Authority
HK
Hong Kong
Prior art keywords
receptor agonists
tetrahydrocarbazole derivatives
tetrahydrocarbazole
derivatives
agonists
Prior art date
Application number
HK98116054A
Other languages
English (en)
Inventor
Francis David King
Laramie Mary Gaster
Alberto Julio Kaumann
Rodney Christopher Young
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10697363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1014669(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of HK1014669A1 publication Critical patent/HK1014669A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK98116054A 1991-06-26 1998-12-28 Use of tetrahydrocarbazole derivatives as 5ht1-receptor agonists HK1014669A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919113802A GB9113802D0 (en) 1991-06-26 1991-06-26 Medicaments
PCT/GB1992/001082 WO1993000086A1 (en) 1991-06-26 1992-06-17 Use of tetrahydrocarbazone derivatives as 5ht1 receptor agonists

Publications (1)

Publication Number Publication Date
HK1014669A1 true HK1014669A1 (en) 1999-09-30

Family

ID=10697363

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98116054A HK1014669A1 (en) 1991-06-26 1998-12-28 Use of tetrahydrocarbazole derivatives as 5ht1-receptor agonists

Country Status (35)

Country Link
US (2) US5464864A (sv)
EP (1) EP0591280B1 (sv)
JP (1) JP3261502B2 (sv)
KR (1) KR100251571B1 (sv)
CN (1) CN1034072C (sv)
AP (1) AP344A (sv)
AT (1) ATE170746T1 (sv)
BR (2) BR9206237A (sv)
CA (1) CA2113726C (sv)
CZ (3) CZ150696A3 (sv)
DE (2) DE10299042I2 (sv)
DK (1) DK0591280T3 (sv)
FI (1) FI103967B1 (sv)
GB (1) GB9113802D0 (sv)
HK (1) HK1014669A1 (sv)
HU (1) HU218907B (sv)
IE (1) IE922062A1 (sv)
IL (4) IL117104A (sv)
LU (1) LU90939I2 (sv)
MA (1) MA22563A1 (sv)
MX (1) MX9203444A (sv)
NL (1) NL300103I2 (sv)
NO (2) NO304774B1 (sv)
NZ (1) NZ243288A (sv)
PL (3) PL171034B1 (sv)
PT (1) PT100620B (sv)
RU (1) RU2137474C1 (sv)
SA (1) SA92130141B1 (sv)
SG (1) SG47877A1 (sv)
SI (1) SI9200125B (sv)
SK (3) SK280907B6 (sv)
TW (1) TW214544B (sv)
UA (1) UA41254C2 (sv)
WO (1) WO1993000086A1 (sv)
ZA (1) ZA924658B (sv)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226530D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5616603A (en) * 1995-05-26 1997-04-01 Smithkline Beecham Plc Enantiomers of carbazole derivatives as 5-HT1 -like agonists
GB9226566D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5618948A (en) * 1995-05-26 1997-04-08 Smithkline Beecham P.L.C. Process for preparing an enantiomer of a carbazole derivative
EP0749962B1 (en) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles
US5917054A (en) * 1995-07-18 1999-06-29 Smithkline Beecham P.L.C. Process for preparing enantiomers of carbazole derivatives as 5-HT1 -like agonists
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9723061D0 (en) * 1997-10-31 1998-01-07 Vanguard Medica Ltd Medicaments
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
GB9808069D0 (en) * 1998-04-16 1998-06-17 Vanguard Medica Ltd Novel processes
GB9817911D0 (en) * 1998-08-17 1998-10-14 Vanguard Medica Ltd New use
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
EP1523486B1 (en) 2002-06-21 2007-11-07 Suven Life Sciences Limited Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
DK1537113T5 (da) 2002-06-21 2011-01-10 Suven Life Sciences Ltd Arylalkylindoler med serotoninreceptoraffinitet anvendelige som terapeutiske midler, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
ES2425143T3 (es) 2002-11-28 2013-10-11 Suven Life Sciences Limited N-Arilsulfonil-3-aminoalcoxiindoles
DK1581492T3 (da) 2002-11-28 2008-11-10 Suven Life Sciences Ltd N-arylsulfonyl-3-substituerede indoler med serotoninreceptoraffinitet, fremgangsmåde til fremstilling heraf og en farmaceutisk sammensætning indeholdende disse
EA009367B1 (ru) 2002-12-18 2007-12-28 Сувен Лайф Сайенсиз Лимитед ПРОИЗВОДНЫЕ 5-ТИА-5-ДИОКСО-4b-АЗАИНДЕНО[2,1-a]ИНДЕНА, ОБЛАДАЮЩИЕ АФФИННОСТЬЮ К РЕЦЕПТОРУ СЕРОТОНИНА
JP5220013B2 (ja) * 2006-08-07 2013-06-26 アクテリオン ファーマシューティカルズ リミテッド （３−アミノ−１，２，３，４−テトラヒドロ−９ｈ−カルバゾール−９−イル）−酢酸誘導体
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
WO2008097664A1 (en) 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20090069399A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched frovatriptan
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
WO2010073253A1 (en) * 2008-12-22 2010-07-01 Natco Pharma Limited Method for preparing an optically active frovatriptan
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
WO2011050140A1 (en) 2009-10-22 2011-04-28 Blue Fury Consulting, L.L.C. Posterior cervical fusion system and techniques
US10098674B2 (en) 2009-10-22 2018-10-16 Nuvasive, Inc. System and method for posterior cervical fusion
PL2734634T3 (pl) 2011-07-22 2020-03-31 The University Of Chicago Igf-1 do zastosowania do leczenia migreny
CA2895816C (en) 2012-12-21 2021-02-23 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
EP2816030A1 (en) 2013-06-20 2014-12-24 Duke Chem, S. A. Process for the preparation of frovatriptan and its enantiomer
GB201312768D0 (en) * 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642816A (en) * 1967-08-10 1972-02-15 Sterling Drug Inc 3-acetamido-1 2 3 4-tetrahydrocarbazole
US3959309A (en) * 1968-01-24 1976-05-25 Sterling Drug Inc. 3-Amido-1,2,3,4-tetrahydrocarbazoles
US4062864A (en) * 1968-01-24 1977-12-13 Sterling Drug Inc. 3-Hydroxy carbazole derivatives
US3592824A (en) * 1970-03-12 1971-07-13 Miles Lab 3-substituted amino-1,2,3,4-tetrahydrocarbazoles
US4172834A (en) * 1971-08-16 1979-10-30 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
BE787537A (fr) * 1971-08-16 1973-02-14 Sterling Drug Inc Tetrahydrocarbazoles
US4257952A (en) * 1977-06-06 1981-03-24 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
US4254134A (en) * 1978-03-17 1981-03-03 Endo Laboratories, Inc. Antidepressant 2-amino- and -2-(substituted amino)-cis-hexahydro-carbazoles
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate

Also Published As

Publication number Publication date
IL117104A0 (en) 1996-06-18
DE10299042I2 (de) 2005-02-03
EP0591280B1 (en) 1998-09-09
HUT68961A (en) 1995-08-28
FI935842A0 (fi) 1993-12-23
DK0591280T3 (da) 1999-02-15
PL171034B1 (en) 1997-02-28
EP0591280A1 (en) 1994-04-13
SI9200125A (en) 1992-12-31
NO934800D0 (no) 1993-12-23
CZ150596A3 (en) 1997-05-14
HU218907B (hu) 2000-12-28
IL117105A0 (en) 1996-06-18
FI103967B (sv) 1999-10-29
CN1069726A (zh) 1993-03-10
SK280905B6 (sk) 2000-09-12
CN1034072C (zh) 1997-02-19
PL169410B1 (pl) 1996-07-31
DE69226953T2 (de) 1999-05-12
NZ243288A (en) 1994-09-27
US5464864A (en) 1995-11-07
IL117105A (en) 1998-01-04
JP3261502B2 (ja) 2002-03-04
CZ282327B6 (cs) 1997-06-11
PT100620B (pt) 1999-01-29
CZ282083B6 (cs) 1997-05-14
SI9200125B (en) 2001-12-31
NL300103I1 (nl) 2002-12-02
SK280906B6 (sk) 2000-09-12
AU652842B2 (en) 1994-09-08
MA22563A1 (fr) 1992-12-31
DE69226953D1 (de) 1998-10-15
AP9200403A0 (en) 1992-07-31
UA41254C2 (uk) 2001-09-17
NO2005011I1 (no) 2005-05-18
BR1100460A (pt) 2000-07-18
CZ150696A3 (en) 1997-06-11
CA2113726A1 (en) 1993-01-07
AU1977592A (en) 1993-01-25
DE10299042I1 (de) 2003-02-20
ZA924658B (en) 1993-12-24
WO1993000086A1 (en) 1993-01-07
US5637611A (en) 1997-06-10
SK280907B6 (sk) 2000-09-12
SK131993A3 (en) 1994-06-08
ATE170746T1 (de) 1998-09-15
PL169392B1 (pl) 1996-07-31
SA92130141B1 (ar) 2005-12-18
AP344A (en) 1994-07-05
FI103967B1 (sv) 1999-10-29
RU2137474C1 (ru) 1999-09-20
BR9206237A (pt) 1995-04-11
CZ282061B6 (cs) 1997-05-14
MX9203444A (es) 1993-12-01
NO2005011I2 (no) 2008-02-11
NO304774B1 (no) 1999-02-15
IL117104A (en) 1997-09-30
JPH06508827A (ja) 1994-10-06
IL102322A (en) 1997-09-30
IE922062A1 (en) 1992-12-30
FI935842A (fi) 1993-12-23
IL102322A0 (en) 1993-01-14
KR100251571B1 (ko) 2000-07-01
PT100620A (pt) 1993-09-30
NL300103I2 (nl) 2003-02-03
SG47877A1 (en) 1998-04-17
NO934800L (no) 1993-12-23
CZ286193A3 (en) 1994-07-13
LU90939I2 (fr) 2002-09-24
GB9113802D0 (en) 1991-08-14
CA2113726C (en) 2008-02-19
TW214544B (sv) 1993-10-11

Similar Documents

Publication Publication Date Title
HK1014669A1 (en) Use of tetrahydrocarbazole derivatives as 5ht1-receptor agonists
EP0516349A3 (en) 2-hydroxy-2-phenylethylamine derivatives as beta-3-adrenoceptor agonists
EP0429257A3 (en) Indole derivatives
AU3952693A (en) Indole derivatives as 5-HT1-like agonists
AU2280592A (en) New heterocyclic derivatives
EP0512350A3 (en) Indole derivatives
EP0438690A3 (en) Substituted pyrazolin derivatives
HUT73670A (en) Use of indole derivatives as 5ht1 antagonists
ZA905524B (en) Indole derivatives
AU2654692A (en) Pyrrolobenzoxazine derivatives as 5-ht agonists and antagonists
GB9116732D0 (en) Indole derivatives
GB9124733D0 (en) Derivatives of poly-4-amino-2-carboxy-1-methyl compounds
GB9102804D0 (en) Heterocyclic derivatives
YU132088A (en) 4-amino-substituted derivatives of 1,2-dihydronaphtaline
HU9201889D0 (en) New cephem derivatives
EP0650723A3 (en) New pharmaceutical uses of forskolin derivatives.
AU2949192A (en) Arylethanolamine derivatives and their use as beta-3-adrenoceptor agonists
IL102539A0 (en) Preparation of 17beta-substituted-4-aza 5alpha-androstan-3-one derivatives
EP0468927A3 (en) Derivatives of carboxymethylcyclopropane
GB9121205D0 (en) Derivatives of poly-5-amino-3-carboxy-1-methyl compounds
HU9400358D0 (en) Use of quinoziline derivatives as orexigenics
EP0519370A3 (en) Heterocyclic derivatives
AU636921B2 (en) Benzylpyrrolidine derivatives as dopamine agonists
IE900317L (en) Use of oxoquinazoline derivatives
ZA883493B (en) Dopamine derivatives

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20120616